Departement
Klinische Forschung
Achtung: Diese Seite kann nur von Administratoren besucht werden, da Sie nicht freigeschalten wurde.
Zurück
Publications Heinzelmann Viola

An interdisciplinary team-training protocol for robotic gynecologic surgery improves operating time and costs: analysis of a 4-year experience in a university hospital setting.

Vigo F; Egg R; Schoetzau A; Montavon C; Brezak M; Heinzelmann-Schwarz V; Kavvadias T. Journal of robotic surgery. 2022.

Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors.

Natoli M; Hatje K; Gulati P; Junker F; Herzig P; Jiang Z; Davydov II; Germann M; Trüb M; Marbach D; Zwick A; Weber P; Seeber S; Wiese M; Lardinois D; Heinzelmann-Schwarz V; Rosenberg R; Tietze L; Mertz KD; Umaña P; Klein C; Codarri-Deak L; Kao H; Zippelius A. Journal for ImmunoTherapy of Cancer. 2022.

Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines.

Fedier A; Maggi N; Tozzi A; Disler M; Coelho R; Jacob F; Heinzelmann-Schwarz V. International journal of oncology. 2022.

Glycosphingolipids are mediators of cancer plasticity through independent signaling pathways.

Cumin C; Huang YL; Rossdam C; Ruoff F; Céspedes SP; Liang CY; Lombardo FC; Coelho R; Rimmer N; Konantz M; López MN; Alam S; Schmidt A; Calabrese D; Fedier A; Vlajnic T; von Itzstein M; Templin M; Buettner FFR; Everest-Dass A; Heinzelmann-Schwarz V; Jacob F. Cell Reports. 2022.

How does colpocleisis for pelvic organ prolapse in older women affect quality of life, body image, and sexuality? A critical review of the literature.

Felder L; Heinzelmann-Schwarz V; Kavvadias T. Women's health (London, England). 2022.

Impact of disease progression on health-related quality of life of advanced ovarian cancer patients - Pooled analysis from the PRIMA trial.

Chase DM; Marín MR; Backes F; Han S; Graybill W; Mirza MR; Pothuri B; Mangili G; O'Malley DM; Berton D; Willmott L; Baumann K; Coleman RL; Safra T; Heinzelmann-Schwarz V; Lorusso D; Karl FM; Woodward T; Monk BJ; Gonzalez-Martin A; PRIMA/ENGOT-OV26/GOG-3012 Investigators.. Gynecologic oncology. 2022.

Intention to Inform Relatives, Rates of Cascade Testing, and Preference for Patient-Mediated Communication in Families Concerned with Hereditary Breast and Ovarian Cancer and Lynch Syndrome: The Swiss CASCADE Cohort.

Sarki M; Ming C; Aissaoui S; Bürki N; Caiata-Zufferey M; Erlanger TE; Graffeo-Galbiati R; Heinimann K; Heinzelmann-Schwarz V; Monnerat C; Probst-Hensch N; Rabaglio M; Zürrer-Härdi U; Chappuis PO; Katapodi MC; On Behalf Of The Cascade Consortium. Cancers. 2022.

Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial.

McLaughlin PMJ; Klar M; Zwimpfer TA; Dutilh G; Vetter M; Marth C; du Bois A; Schade-Brittinger C; Reuss A; Bommer C; Kurzeder C; Heinzelmann-Schwarz V. BMC CANCER. 2022.

Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancer.

Coelho R; Tozzi A; Disler M; Lombardo F; Fedier A; López MN; Freuler F; Jacob F; Heinzelmann-Schwarz V. Cell Death & Disease. 2022.

Perioperative management with ferric carboxymaltose and tranexamic acid to reduce transfusion rate in gynaecological carcinoma surgery (TRANAFER-Study): study protocol for a single-blind, monocentre, randomised trial.

Amstad G; Geiger J; Werlen L; Montavon C; Heinzelmann V. BMJ Open. 2022.

Swiss cost-effectiveness analysis of universal screening for Lynch syndrome of patients with colorectal cancer followed by cascade genetic testing of relatives.

Salikhanov I; Heinimann K; Chappuis P; Buerki N; Graffeo R; Heinzelmann V; Rabaglio M; Taborelli M; Wieser S; Katapodi MC. Journal of medical genetics. 2022.

The double S technique to achieve aesthetic flat closure after conventional mastectomy.

Steffens D; Kappos EA; Lunger A; Schwab FD; Zehnpfennig L; Weber WP; Haug M; Heinzelmann-Schwarz V; Kurzeder C. World Journal of Surgical Oncology. 2022.

The metastatic spread of breast cancer accelerates during sleep.

Diamantopoulou Z; Castro-Giner F; Schwab FD; Foerster C; Saini M; Budinjas S; Strittmatter K; Krol I; Seifert B; Heinzelmann-Schwarz V; Kurzeder C; Rochlitz C; Vetter M; Weber WP; Aceto N. Nature. 2022.

Comparison of 2D 4K vs. 3D HD laparoscopic imaging systems using a pelvitrainer model: a randomized controlled study.

Zwimpfer TA; Wismer C; Fellmann-Fischer B; Geiger J; Schötzau A; Heinzelmann-Schwarz V. Updates in surgery. 2021.

Establishing standardized immune phenotyping of metastatic melanoma by digital pathology

Sobottka B.; Nowak M.; Frei A.L.; Haberecker M.; Merki S.; Aebersold R.; Ak M.; Al-Quaddoomi F.S.; Albinus J.; Alborelli I.; Andani S.; Attinger P.-O.; Bacac M.; Baumhoer D.; Beck-Schimmer B.; Beerenwinkel N.; Beisel C.; Bernasconi L.; Bertolini A.; Bodenmiller B.; Bonilla X.; Casanova R.; Chevrier S.; Chicherova N.; D'Costa M.; Danenberg E.; Davidson N.; Draganmoch M.-A.; Engler S.; Erkens M.; Eschbach K.; Esposito C.; Fedier A.; Ferreira P.; Ficek J.; Frey B.; Goetze S.; Grob L.; Gut G.; Gunther D.; Haberecker M.; Haeuptle P.; Heinzelmann-Schwarz V.; Herter S.; Holtackers R.; Huesser T.; Irmisch A.; Jacob F.; Jacobs A.; Jaeger T.M.; Jahn K.; James A.R.; Jermann P.M.; Kahles A.; Kahraman A.; Kuebler W.; Kuipers J.; Kunze C.P.; Kurzeder C.; Lehmann K.-V.; Lugert S.; Maass G.; Manz M.G.; Markolin P.; Mena J.; Menzel U.; Metzler J.M.; Miglino N.; Milani E.S.; Muenst S.; Murri R.; Ng C.K.Y.; Nicolet S.; Pedrioli P.G.A.; Pelkmans L.; Piscuoglio S.; Prummer M.; Ritter M.; Rommel C.; Rosano-Gonzalez M.L.; Ratsch G.; Santacroce N.; del Castillo J.S.; Schlenker R.; Schwalie P.C.; Schwan S.; Schar T.; Senti G.; Singer F.; Sivapatham S.; Snijder B.; Sreedharan V.T.; Stark S.; Stekhoven D.J.; Theocharides A.P.A.; Thomas T.M.; Tolnay M.; Tosevski V.; Toussaint N.C.; Tuncel M.A.; Tusup M.; Van Drogen A.; Vetter M.; Vlajnic T.; Weber S.; Weber W.P.; Wegmann R.; Weller M.; Wendt F.; Wey N.; Wicki A.; Wildschut M.H.; Wollscheid B.; Yu S.; Ziegler J.; Zimmermann M.; Zoche M.; Zuend G.; Levesque M.P.; Dummer R.; Moch H.; Koelzer V.H.. Laboratory Investigation. 2021.

Genetic Literacy and Communication of Genetic Information in Families Concerned with Hereditary Breast and Ovarian Cancer: A Cross-Study Comparison in Two Countries and within a Timeframe of More Than 10 Years.

Pedrazzani C; Ming C; Bürki N; Caiata-Zufferey M; Chappuis PO; Duquette D; Heinimann K; Heinzelmann-Schwarz V; Graffeo-Galbiati R; Merajver SD; Milliron KJ; Monnerat C; Pagani O; Rabaglio M; Katapodi MC. Cancers. 2021.

High-grade serous peritoneal cancer follows a high stromal response signature and shows worse outcome than ovarian cancer.

Jacob F; Marchetti RL; Kind AB; Russell K; Schoetzau A; Heinzelmann-Schwarz VA. Molecular oncology. 2021.

Integrated functional and spatial profiling of tumour immune responses induced by immunotherapy: the <i>iPROFILER</i> platform.

Koelzer VH; Herzig P; Zlobec I; Heinzelmann V; Lardinois D; Walseng E; Rader C; Mertz KD; Zippelius A; Thommen DS. Immuno-oncology technology. 2021.

L1CAM is not a reliable predictor for lymph node metastases in endometrial cancer, but L1CAM positive patients benefit from radiotherapy.

Zeiter D; Vlajnic T; Schötzau A; Heinzelmann-Schwarz V; Montavon C. Journal of Cancer. 2021.

Managing Cancer as a Family Disease - Feasibility, Satisfaction and Family Functioning after Short-Time Counselling for Families with Parental Cancer

Ehrbar V.; Roos S.; Denzinger A.; Bingisser M.B.; Scherer S.; Gaab J.; Vetter M.; Heinzelmann-Schwarz V.; Urech C.. Family Journal. 2021.

Plinabulin, a Distinct Microtubule-Targeting Chemotherapy, Promotes M1-Like Macrophage Polarization and Anti-tumor Immunity.

Natoli M; Herzig P; Pishali Bejestani E; Buchi M; Ritschard R; Lloyd GK; Mohanlal R; Tonra JR; Huang L; Heinzelmann V; Trüb M; Zippelius A; Kashyap AS. Frontiers in Oncology. 2021.

The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision support.

Irmisch A; Bonilla X; Chevrier S; Lehmann KV; Singer F; Toussaint NC; Esposito C; Mena J; Milani ES; Casanova R; Stekhoven DJ; Wegmann R; Jacob F; Sobottka B; Goetze S; Kuipers J; Sarabia Del Castillo J; Prummer M; Tuncel MA; Menzel U; Jacobs A; Engler S; Sivapatham S; Frei AL; Gut G; Ficek J; Miglino N; Tumor Profiler Consortium.; Aebersold R; Bacac M; Beerenwinkel N; Beisel C; Bodenmiller B; Dummer R; Heinzelmann-Schwarz V; Koelzer VH; Manz MG; Moch H; Pelkmans L; Snijder B; Theocharides APA; Tolnay M; Wicki A; Wollscheid B; Rätsch G; Levesque MP. Cancer cell. 2021.

Using a Tailored Digital Health Intervention for Family Communication and Cascade Genetic Testing in Swiss and Korean Families With Hereditary Breast and Ovarian Cancer: Protocol for the DIALOGUE Study.

Kim S; Aceti M; Baroutsou V; Bürki N; Caiata-Zufferey M; Cattaneo M; Chappuis PO; Ciorba FM; Graffeo-Galbiati R; Heinzelmann-Schwarz V; Jeong J; Jung MM; Kim SW; Kim J; Lim MC; Ming C; Monnerat C; Park HS; Park SH; Pedrazzani CA; Rabaglio M; Ryu JM; Saccilotto R; Wieser S; Zürrer-Härdi U; Katapodi MC. JMIR research protocols. 2021.

Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis.

Le Page C; Rahimi K; Rodrigues M; Heinzelmann-Schwarz V; Recio N; Tommasi S; Bataillon G; Portelance L; Golmard L; Meunier L; Tonin PN; Gotlieb W; Yasmeen A; Ray-Coquard I; Labidi-Galy SI; Provencher D; Mes-Masson AM. Gynecologic oncology. 2020.

Collagen-rich omentum is a premetastatic niche for integrin α2-mediated peritoneal metastasis.

Huang YL; Liang CY; Ritz D; Coelho R; Septiadi D; Estermann M; Cumin C; Rimmer N; Schötzau A; Núñez López M; Fedier A; Konantz M; Vlajnic T; Calabrese D; Lengerke C; David L; Rothen-Rutishauser B; Jacob F; Heinzelmann-Schwarz V. eLife. 2020.

Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer.

Trüb M; Uhlenbrock F; Claus C; Herzig P; Thelen M; Karanikas V; Bacac M; Amann M; Albrecht R; Ferrara-Koller C; Thommen D; Rothschield S; Savic Prince S; Mertz KD; Cathomas G; Rosenberg R; Heinzelmann-Schwarz V; Wiese M; Lardinois D; Umana P; Klein C; Laubli H; Kashyap AS; Zippelius A. Journal for ImmunoTherapy of Cancer. 2020.

L1 Cell Adhesion Molecule Confers Radioresistance to Ovarian Cancer and Defines a New Cancer Stem Cell Population.

Terraneo N; Jacob F; Peitzsch C; Dubrovska A; Krudewig C; Huang YL; Heinzelmann-Schwarz V; Schibli R; Béhé M; Grünberg J. Cancers. 2020.

Patient-derived and artificial ascites have minor effects on MeT-5A mesothelial cells and do not facilitate ovarian cancer cell adhesion.

Estermann M; Huang YL; Septiadi D; Ritz D; Liang CY; Jacob F; Drasler B; Petri-Fink A; Heinzelmann-Schwarz V; Rothen-Rutishauser B. PLoS One. 2020.

Regulation of invasion and peritoneal dissemination of ovarian cancer by mesothelin manipulation.

Coelho R; Ricardo S; Amaral AL; Huang YL; Nunes M; Neves JP; Mendes N; López MN; Bartosch C; Ferreira V; Portugal R; Lopes JM; Almeida R; Heinzelmann-Schwarz V; Jacob F; David L. Oncogenesis. 2020.

Reply to comment on: Wiser et al. Ovarian cancer in Switzerland: incidence and treatment according to hospital registry data. Swiss Med Wkly.2018;148:w14647.

Wieser S; Schmidt M; Kind AB; Heinzelmann-Schwarz VA. . 2020.

Should MMMT still be treated with adjuvant taxane-based combination chemotherapy?

Heinzelmann-Schwarz V; Kind AB; Vetter M; Russell K; Omar S; Schoetzau A; Hoeck K; Fink D; Friedlander ML; Hacker NF. Journal of Cancer Research and Clinical Oncology. 2020.

A forgotten disease: Pelvic congestion syndrome as a cause of chronic lower abdominal pain.

Jurga-Karwacka A; Karwacki GM; Schoetzau A; Zech CJ; Heinzelmann-Schwarz V; Schwab FD. PLoS One. 2019.

A Targeted Mass Spectrometry Strategy for Developing Proteomic Biomarkers: A Case Study of Epithelial Ovarian Cancer.

Hüttenhain R; Choi M; Martin de la Fuente L; Oehl K; Chang CY; Zimmermann AK; Malander S; Olsson H; Surinova S; Clough T; Heinzelmann-Schwarz V; Wild PJ; Dinulescu DM; Niméus E; Vitek O; Aebersold R. Molecular & cellular proteomics : MCP. 2019.

Circulating Tumor Cell Clustering Shapes DNA Methylation to Enable Metastasis Seeding.

Gkountela S; Castro-Giner F; Szczerba BM; Vetter M; Landin J; Scherrer R; Krol I; Scheidmann MC; Beisel C; Stirnimann CU; Kurzeder C; Heinzelmann-Schwarz V; Rochlitz C; Weber WP; Aceto N. Cell. 2019.

Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers.

Labidi-Galy SI; de La Motte Rouge T; Derbel O; Wolfer A; Kalbacher E; Olivier T; Combes JD; Heimgartner-Hu K; Tredan O; Guevara H; Heudel PE; Reverdy T; Bazan F; Heinzelmann-Schwarz V; Fehr M; de Castelbajac V; Vaflard P; Crivelli L; Bonadona V; Viassolo V; Buisson A; Golmard L; Rodrigues M; Ray-Coquard I. Gynecologic oncology. 2019.

Fibrin-thrombin sealant does not reduce lymphocele formation in patients with inguinofemoral lymphadenectomy for vulvar cancer.

Saner FA; Schötzau A; Mackay G; Heinzelmann-Schwarz V; Montavon Sartorius C. Cancer Management and Research. 2019.

Neutrophils escort circulating tumour cells to enable cell cycle progression.

Szczerba BM; Castro-Giner F; Vetter M; Krol I; Gkountela S; Landin J; Scheidmann MC; Donato C; Scherrer R; Singer J; Beisel C; Kurzeder C; Heinzelmann-Schwarz V; Rochlitz C; Weber WP; Beerenwinkel N; Aceto N. Nature. 2019.

Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response.

Baettig F; Vlajnic T; Vetter M; Glatz K; Hench J; Frank S; Bihl M; Lopez R; Dobbie M; Heinzelmann-Schwarz V; Montavon C. Journal for ImmunoTherapy of Cancer. 2019.

Outcome in serous ovarian cancer is not associated with LATS expression.

Montavon C; Stricker GR; Schoetzau A; Heinzelmann-Schwarz V; Jacob F; Fedier A. Journal of Cancer Research and Clinical Oncology. 2019.

Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy.

Claus C; Ferrara C; Xu W; Sam J; Lang S; Uhlenbrock F; Albrecht R; Herter S; Schlenker R; Hüsser T; Diggelmann S; Challier J; Mössner E; Hosse RJ; Hofer T; Brünker P; Joseph C; Benz J; Ringler P; Stahlberg H; Lauer M; Perro M; Chen S; Küttel C; Bhavani Mohan PL; Nicolini V; Birk MC; Ongaro A; Prince C; Gianotti R; Dugan G; Whitlow CT; Solingapuram Sai KK; Caudell DL; Burgos-Rodriguez AG; Cline JM; Hettich M; Ceppi M; Giusti AM; Crameri F; Driessen W; Morcos PN; Freimoser-Grundschober A; Levitsky V; Amann M; Grau-Richards S; von Hirschheydt T; Tournaviti S; Mølhøj M; Fauti T; Heinzelmann-Schwarz V; Teichgräber V; Colombetti S; Bacac M; Zippelius A; Klein C; Umaña P. Science translational medicine. 2019.

ABO blood groups as a prognostic factor for recurrence in ovarian and vulvar cancer.

Montavon Sartorius C; Schoetzau A; Kettelhack H; Fink D; Hacker NF; Fedier A; Jacob F; Heinzelmann-Schwarz V. PLoS One. 2018.

Challenges and Opportunities for Cancer Predisposition Cascade Screening for Hereditary Breast and Ovarian Cancer and Lynch Syndrome in Switzerland: Findings from an International Workshop.

Nikolaidis C; Ming C; Pedrazzani C; van der Horst T; Kaiser-Grolimund A; Ademi Z; Bührer-Landolt R; Bürki N; Caiata-Zufferey M; Champion V; Chappuis PO; Kohler C; Erlanger TE; Graffeo R; Hampel H; Heinimann K; Heinzelmann-Schwarz V; Kurzeder C; Monnerat C; Northouse LL; Pagani O; Probst-Hensch N; Rabaglio M; Schoenau E; Sijbrands EJG; Taborelli M; Urech C; Viassolo V; Wieser S; Katapodi MC; for the CASCADE Consortium.. Public health genomics. 2018.

Correction to: The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Kommission Ovar, AGO Study Group, North-Eastern German Society of Gynaecologic Oncology (NOGGO), AGO Austria and AGO Switzerland.

Dueckelmann AM; Fink D; Harter P; Heinzelmann V; Marth C; Mueller M; Reinthaller A; Tamussino K; Wimberger P; Sehouli J. Archives of gynecology and obstetrics. 2018.

Denosumab treatment is associated with the absence of circulating tumor cells in patients with breast cancer.

Vetter M; Landin J; Szczerba BM; Castro-Giner F; Gkountela S; Donato C; Krol I; Scherrer R; Balmelli C; Malinovska A; Zippelius A; Kurzeder C; Heinzelmann-Schwarz V; Weber WP; Rochlitz C; Aceto N. BREAST CANCER RESEARCH. 2018.

Diaphragmatic smears are not of additional benefit in the detection of peritoneal spread in gynecological cancers.

Montavon C; Mirza U; Fedier A; Schoetzau A; Zanetti Dällenbach R; Heinzelmann-Schwarz V. Experimental and Therapeutic Medicine. 2018.

Impact of the new FIGO 2013 classification on prognosis of stage I epithelial ovarian cancers.

Montavon Sartorius C; Mirza U; Schötzau A; Mackay G; Fink D; Hacker NF; Heinzelmann-Schwarz V. Cancer Management and Research. 2018.

Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients.

Heinzelmann-Schwarz V; Knipprath Mészaros A; Stadlmann S; Jacob F; Schoetzau A; Russell K; Friedlander M; Singer G; Vetter M. Gynecologic oncology. 2018.

Ovarian cancer in Switzerland: incidence and treatment according to hospital registry data.

Wieser S; Schmidt M; Kind AB; Heinzelmann-Schwarz VA. Swiss Medical Weekly. 2018.

Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells.

Stanczak MA; Siddiqui SS; Trefny MP; Thommen DS; Boligan KF; von Gunten S; Tzankov A; Tietze L; Lardinois D; Heinzelmann-Schwarz V; von Bergwelt-Baildon M; Zhang W; Lenz HJ; Han Y; Amos CI; Syedbasha M; Egli A; Stenner F; Speiser DE; Varki A; Zippelius A; Läubli H. Journal of Clinical Investigation. 2018.

The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the "Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)", the Swiss and Austrian AGO, and the North-Eastern German Society of Gynaecologic Oncology.

Dueckelmann AM; Fink D; Harter P; Heinzelmann V; Marth C; Mueller M; Reinthaller A; Tamussino K; Wimberger P; Sehouli J. Archives of gynecology and obstetrics. 2018.

Transition of Mesenchymal and Epithelial Cancer Cells Depends on α1-4 Galactosyltransferase-Mediated Glycosphingolipids.

Jacob F; Alam S; Konantz M; Liang CY; Kohler RS; Everest-Dass AV; Huang YL; Rimmer N; Fedier A; Schötzau A; Lopez MN; Packer NH; Lengerke C; Heinzelmann-Schwarz V. Cancer research. 2018.

Cancer Predisposition Cascade Screening for Hereditary Breast/Ovarian Cancer and Lynch Syndromes in Switzerland: Study Protocol.

Katapodi MC; Viassolo V; Caiata-Zufferey M; Nikolaidis C; Bührer-Landolt R; Buerki N; Graffeo R; Horváth HC; Kurzeder C; Rabaglio M; Scharfe M; Urech C; Erlanger TE; Probst-Hensch N; Heinimann K; Heinzelmann-Schwarz V; Pagani O; Chappuis PO. JMIR research protocols. 2017.

Intra-, peri- and postoperative complications in pelvic organ prolapse surgery in elderly women

Kornig, M. P.; Bruhlmann, E.; Heinzelmann-Schwarz, V; Gunthert, A.; Christmann, C.. BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY. 2017.

MELK expression in ovarian cancer correlates with poor outcome and its inhibition by OTSSP167 abrogates proliferation and viability of ovarian cancer cells.

Kohler RS; Kettelhack H; Knipprath-Mészaros AM; Fedier A; Schoetzau A; Jacob F; Heinzelmann-Schwarz V. Gynecologic oncology. 2017.

Naturally occurring anti-glycan antibodies binding to Globo H-expressing cells identify ovarian cancer patients.

Pochechueva T; Alam S; Schötzau A; Chinarev A; Bovin NV; Hacker NF; Jacob F; Heinzelmann-Schwarz V. Journal of Ovarian Research. 2017.

Spontaneous Remission of Severe Systemic Langerhans Cell Histiocytosis with Bladder Involvement: A Case Study.

Magaton IM; Tzankov A; Krasniqi F; Rottenburger C; Zanetti-Daellenbach R; Grendelmeier P; Heinzelmann-Schwarz V; Mayr M; Schwab FD. Case Rep Oncol (ONLINE-AUSGABE). 2017.

Tissue glycomics distinguish tumour sites in women with advanced serous adenocarcinoma

Anugraham, Merrina; Jacob, Francis; Everest-Dass, Arun V.; Schoetzau, Andreas; Nixdorf, Sheri; Hacker, Neville F.; Fink, Daniel; Heinzelmann-Schwarz, Viola; Packer, Nicolle H.. Molecular oncology. 2017.

Blood Plasma-Derived Anti-Glycan Antibodies to Sialylated and Sulfated Glycans Identify Ovarian Cancer Patients.

Pochechueva T; Chinarev A; Schoetzau A; Fedier A; Bovin NV; Hacker NF; Jacob F; Heinzelmann-Schwarz V. PLoS One. 2016.

Epigenetic activation of MGAT3 and corresponding bisecting GlcNAc shortens the survival of cancer patients.

Kohler RS; Anugraham M; López MN; Xiao C; Schoetzau A; Hettich T; Schlotterbeck G; Fedier A; Jacob F; Heinzelmann-Schwarz V. Oncotarget. 2016.

Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor.

Schreiner J; Thommen DS; Herzig P; Bacac M; Klein C; Roller A; Belousov A; Levitsky V; Savic S; Moersig W; Uhlenbrock F; Heinzelmann-Schwarz VA; Umana P; Pisa P; von Bergwelt-Baildon M; Lardinois D; Müller P; Karanikas V; Zippelius A. OncoImmunology. 2016.

Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor.

Schreiner J; Thommen DS; Herzig P; Bacac M; Klein C; Roller A; Belousov A; Levitsky V; Savic S; Moersig W; Uhlenbrock F; Heinzelmann-Schwarz VA; Umana P; Pisa P; von Bergwelt-Baildon M; Lardinois D; Müller P; Karanikas V; Zippelius A. OncoImmunology. 2016.

HIGH-GRADE SEROUS OVARIAN AND PERITONEAL CANCERS DISPLAY DISTINCT GENETIC AND POST-TRANSLATIONAL SIGNATURES -A CRITERION TO TREAT THEM DIFFERENTLY?

Jacob, F.; Anugraham, M.; Schotzau, A.; Everest-Dass, A.; Bovin, N.; Huflejt, M. E.; Fedier, A.; Hacker, N.; Fink, D.; Packer, N.; Heinzelmann-Schwarz, V.. International Journal of Gynecological Cancer. 2016.

Improved Detection Rate of Ovarian Cancer Using a 2-Step Triage Model of the Risk of Malignancy Index and Expert Sonography in an Outpatient Screening Setting

Manegold-Brauer G.; Buechel J.; Knipprath-Meszaros A.; Schoetzau A.; Hacker N.F.; Tercanli S.; Lapaire O.; Heinzelmann-Schwarz V.. International Journal of Gynecological Cancer. 2016.

Long-term quality of life, satisfaction, pelvic floor symptoms and regret after colpocleisis.

Katsara A; Wight E; Heinzelmann-Schwarz V; Kavvadias T. Archives of gynecology and obstetrics. 2016.

LOW MGAT3 EXPRESSION IDENTIFIES LONG-TERM SURVIVORS WITH HIGH GRADE SEROUS OVARIAN CANCER

Kohler, R. S.; Anugraham, M.; Lopez, M. N. Nunez; Schotzau, A.; Hettich, T.; Schlotterbeck, G.; Fedier, A.; Jacob, F.; Heinzelmann-Schwarz, V.. International Journal of Gynecological Cancer. 2016.

Molecular characterization and comparison of epithelial ovarian carcinoma (EOC) and primary peritoneal carcinoma (PCC)

Knipprath, A. M.; Arguello, D.; Russell, K.; Voss, A.; Heinzelmann-Schwarz, V.. Annals of Oncology. 2016.

Alterations in the mitochondrial responses to PENAO as a mechanism of resistance in ovarian cancer cells.

Decollogne S; Joshi S; Chung SA; Luk PP; Yeo RX; Nixdorf S; Fedier A; Heinzelmann-Schwarz V; Hogg PJ; Dilda PJ. Gynecologic oncology. 2015.

Comment on the letter: the mass cannot be classified as malignant.

Manegold-Brauer G; Heinzelmann-Schwarz V. Archives of gynecology and obstetrics. 2015.

Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion.

Henry C; Llamosas E; Knipprath-Meszaros A; Schoetzau A; Obermann E; Fuenfschilling M; Caduff R; Fink D; Hacker N; Ward R; Heinzelmann-Schwarz V; Ford C. Oncotarget. 2015.

A clinicopathological review of 33 patients with vulvar melanoma identifies c-KIT as a prognostic marker.

Heinzelmann-Schwarz VA; Nixdorf S; Valadan M; Diczbalis M; Olivier J; Otton G; Fedier A; Hacker NF; Scurry JP. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE. 2014.

Antibody-based immunotherapy for ovarian cancer: where are we at?

Tse BW; Collins A; Oehler MK; Zippelius A; Heinzelmann-Schwarz VA. Annals of Oncology. 2014.

Expression of GBGT1 is epigenetically regulated by DNA methylation in ovarian cancer cells.

Jacob F; Hitchins MP; Fedier A; Brennan K; Nixdorf S; Hacker NF; Ward R; Heinzelmann-Schwarz VA. BMC MOLECULAR BIOLOGY. 2014.

Impact of breast cancer family history on tumor detection and tumor size in women newly-diagnosed with invasive breast cancer.

Schwab FD; Bürki N; Huang DJ; Heinzelmann-Schwarz V; Schmid SM; Vetter M; Schötzau A; Güth U. Familial cancer. 2014.

Management of human papillomavirus-related gynecological malignancies.

Heinzelmann-Schwarz VA; Kind AB; Jacob F. Current problems in dermatology. 2014.

Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells.

Müller P; Martin K; Theurich S; Schreiner J; Savic S; Terszowski G; Lardinois D; Heinzelmann-Schwarz VA; Schlaak M; Kvasnicka HM; Spagnoli G; Dirnhofer S; Speiser DE; von Bergwelt-Baildon M; Zippelius A. Cancer immunology research. 2014.

PEGylation of microbead surfaces reduces unspecific antibody binding in glycan-based suspension array.

Pochechueva T; Chinarev A; Bovin N; Fedier A; Jacob F; Heinzelmann-Schwarz V. Journal of Immunological Methods. 2014.

Reliable in vitro studies require appropriate ovarian cancer cell lines.

Jacob F; Nixdorf S; Hacker NF; Heinzelmann-Schwarz VA. Journal of Ovarian Research. 2014.

Specific glycosylation of membrane proteins in epithelial ovarian cancer cell lines: glycan structures reflect gene expression and DNA methylation status.

Anugraham M; Jacob F; Nixdorf S; Everest-Dass AV; Heinzelmann-Schwarz V; Packer NH. Molecular & cellular proteomics : MCP. 2014.

The glycosphingolipid P₁ is an ovarian cancer-associated carbohydrate antigen involved in migration.

Jacob F; Anugraham M; Pochechueva T; Tse BW; Alam S; Guertler R; Bovin NV; Fedier A; Hacker NF; Huflejt ME; Packer N; Heinzelmann-Schwarz VA. British journal of cancer. 2014.

The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity.

Martin K; Müller P; Schreiner J; Prince SS; Lardinois D; Heinzelmann-Schwarz VA; Thommen DS; Zippelius A. Cancer immunology, immunotherapy : CII. 2014.

The non-canonical Wnt ligand, Wnt5a, is upregulated and associated with epithelial to mesenchymal transition in epithelial ovarian cancer.

Ford CE; Punnia-Moorthy G; Henry CE; Llamosas E; Nixdorf S; Olivier J; Caduff R; Ward RL; Heinzelmann-Schwarz V. Gynecologic oncology. 2014.

The special role of ultrasound for screening, staging and surveillance of malignant ovarian tumors: Distinction from other methods of diagnostic imaging

Manegold-Brauer G.; Bellin A.K.; Tercanli S.; Lapaire O.; Heinzelmann-Schwarz V.. Archives of gynecology and obstetrics. 2014.

Bilateral breast masses with a rare etiology.

Thieringer F; Sartorius G; Kalf K; Heinzelmann V; Vetter M. Case reports in oncological medicine. 2013.

Careful Selection of Reference Genes Is Required for Reliable Performance of RT-qPCR in Human Normal and Cancer Cell Lines

Jacob, Francis; Guertler, Rea; Naim, Stephanie; Nixdorf, Sheri; Fedier, Andre; Hacker, Neville F.; Heinzelmann-Schwarz, Viola. PLoS One. 2013.

Meta-analysis of microarray data identifies gas6 expression as an independent predictor of poor survival in ovarian cancer

Buehler M.; Tse B.; Leboucq A.; Jacob F.; Caduff R.; Fink D.; Goldstein D.R.; Heinzelmann-Schwarz V.. BioMed research international. 2013.

Staging for distant metastases in operable breast cancer: a suggested expansion of the ESMO guideline recommendation for staging imaging of node-negative, hormonal receptor-negative disease.

Güth U; Vetter M; Huang DJ; Heinzelmann-Schwarz V. Annals of Oncology. 2013.

The Wnt gatekeeper SFRP4 modulates EMT, cell migration and downstream Wnt signalling in serous ovarian cancer cells.

Ford CE; Jary E; Ma SS; Nixdorf S; Heinzelmann-Schwarz VA; Ward RL. PLoS One. 2013.

Loss of secreted frizzled-related protein 4 correlates with an aggressive phenotype and predicts poor outcome in ovarian cancer patients.

Jacob F; Ukegjini K; Nixdorf S; Ford CE; Olivier J; Caduff R; Scurry JP; Guertler R; Hornung D; Mueller R; Fink DA; Hacker NF; Heinzelmann-Schwarz VA. PLoS One. 2012.

LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin.

Cowin PA; George J; Fereday S; Loehrer E; Van Loo P; Cullinane C; Etemadmoghadam D; Ftouni S; Galletta L; Anglesio MS; Hendley J; Bowes L; Sheppard KE; Christie EL; Pearson RB; Harnett PR; Heinzelmann-Schwarz V; Friedlander M; McNally O; Quinn M; Campbell P; deFazio A; Bowtell DD; Australian Ovarian Cancer Study.. Cancer research. 2012.

Protein significance analysis in selected reaction monitoring (SRM) measurements.

Chang CY; Picotti P; Hüttenhain R; Heinzelmann-Schwarz V; Jovanovic M; Aebersold R; Vitek O. Molecular & cellular proteomics : MCP. 2012.

Serum antiglycan antibody detection of nonmucinous ovarian cancers by using a printed glycan array.

Jacob F; Goldstein DR; Bovin NV; Pochechueva T; Spengler M; Caduff R; Fink D; Vuskovic MI; Huflejt ME; Heinzelmann-Schwarz V. International Journal of Cancer. 2012.

Tumor-associated glycans and their role in gynecological cancers: accelerating translational research by novel high-throughput approaches.

Pochechueva T; Jacob F; Fedier A; Heinzelmann-Schwarz V. Metabolites. 2012.

[Epithelial ovarian cancer - a change of paradigm].

Heinzelmann-Schwarz V. Therapeutische Umschau. Revue therapeutique. 2011.

Comparison of printed glycan array, suspension array and ELISA in the detection of human anti-glycan antibodies.

Pochechueva T; Jacob F; Goldstein DR; Huflejt ME; Chinarev A; Caduff R; Fink D; Hacker N; Bovin NV; Heinzelmann-Schwarz V. Glycoconjugate journal. 2011.

Multiplex suspension array for human anti-carbohydrate antibody profiling.

Pochechueva T; Chinarev A; Spengler M; Korchagina E; Heinzelmann-Schwarz V; Bovin N; Rieben R. ANALYST. 2011.

No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting

Jacob, Francis; Meier, Mara; Caduff, Rosmarie; Goldstein, Darlene; Pochechueva, Tatiana; Hacker, Neville; Fink, Daniel; Heinzelmann-Schwarz, Viola. Gynecologic oncology. 2011.

URI is an oncogene amplified in ovarian cancer cells and is required for their survival.

Theurillat JP; Metzler SC; Henzi N; Djouder N; Helbling M; Zimmermann AK; Jacob F; Soltermann A; Caduff R; Heinzelmann-Schwarz V; Moch H; Krek W. Cancer cell. 2011.

Proteogenomic studies in epithelial ovarian cancer: established knowledge and future needs.

Jacob F; Goldstein DR; Fink D; Heinzelmann-Schwarz V. Biomarkers in Medicine. 2009.

The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro.

O'Brien PM; Davies MJ; Scurry JP; Smith AN; Barton CA; Henderson MJ; Saunders DN; Gloss BS; Patterson KI; Clancy JL; Heinzelmann-Schwarz VA; Murali R; Scolyer RA; Zeng Y; Williams ED; Scurr L; Defazio A; Quinn DI; Watts CK; Hacker NF; Henshall SM; Sutherland RL. British journal of cancer. 2008.

Low meprin alpha expression differentiates primary ovarian mucinous carcinoma from gastrointestinal cancers that commonly metastasise to the ovaries.

Heinzelmann-Schwarz VA; Scolyer RA; Scurry JP; Smith AN; Gardiner-Garden M; Biankin AV; Baron-Hay S; Scott C; Ward RL; Fink D; Hacker NF; Sutherland RL; O'Brien PM. Journal of clinical pathology. 2007.

A distinct molecular profile associated with mucinous epithelial ovarian cancer.

Heinzelmann-Schwarz VA; Gardiner-Garden M; Henshall SM; Scurry JP; Scolyer RA; Smith AN; Bali A; Vanden Bergh P; Baron-Hay S; Scott C; Fink D; Hacker NF; Sutherland RL; O'Brien PM. British journal of cancer. 2006.

Overexpression of the cell adhesion molecules DDR1, claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer

Heinzelmann-Schwarz, VA; Gardiner-Garden, M; Henshall, SM; Scurry, J; Scolyer, RA; Davies, MJ; Heinzelmann, M; Kalish, LH; Bali, A; Kench, JG; Edwards, LS; Vanden Bergh, PM; Hacker, NF; Sutherland, RL; O'Brien, PM. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004.

Role of p53 and ATM in photodynamic therapy-induced apoptosis.

Heinzelmann-Schwarz V; Fedier A; Hornung R; Walt H; Haller U; Fink D. Lasers in Surgery and Medicine. 2003.